Surgical Science Launches Simbionix ANGIO Tab Pro – First-to-Market Ultra-Portable Endovascular Simulator

Today, Surgical Science (NYSE: DDD) announced its new Simbionix ANGIO Tab Pro endovascular simulator. The ANGIO Tab Pro is a first-to-market solution designed for step-by-step training of endovascular interventions – including 30 modules from basic skills to advanced and complex endovascular procedures, and more than 250 patient scenarios. The lightweight construction renders the ANGIO Tab Pro to be an ultra-portable solution, making it ideal for use at conferences, as well as in the physician’s clinic or home.

ROCK HILL, South Carolina, May 17, 2018 – The ANGIO Tab Pro simulator is easy to set-up – requiring significantly less time than traditional simulator solutions. It runs complete procedures with full functionality, and enables physical device introduction as well as deployment using an authentic handle. The angiographic visualization of the anatomy and instrument activity combined with haptic feedback results in a simulator that realistically imitates the look and feel of actual endovascular interventions.

The ANGIO Tab Pro released early to medical device companies and is receiving very positive feedback. “We are using the ANGIO Tab Pro to practice TAVI,” said Nathalie Ganas, TAVI (Transcatheter Aortic Valve Implantation) European training manager, Boston Scientific International. “It is very easy to set-up and use. It’s great to have a simulator that is so easy to carry.”

The ANGIO Tab Pro is the latest addition to Surgical Science’ line of ANGIO Mentor endovascular simulators including ANGIO Mentor Suite and ANGIO Mentor Flex. With a comprehensive suite of modules and patient scenarios, the ANGIO Tab Pro is well-suited for learners of all levels across multiple specialties including: Interventional Cardiology, Interventional Radiology, Vascular Surgery, Cardiothoracic Surgery, Electrophysiology, Interventional Neuroradiology, Neuro Surgery and Trauma.

“We are excited to see the ANGIO Tab Pro join our full line of ANGIO Mentor simulator platforms,” said Ran Bronstein, vice president, chief research and operation officer, healthcare, 3DSystems. ”It was a challenge to have such advanced functionality in such a compact offering, but the need in the marketplace drove us to find innovative solutions that are simple, practical and affordable.”

View the ANGIO Tab Pro introduction video

Experience the ANGIO Tab Pro in booth M12 at EuroPCR, May 22–25 in Paris.

Forward-Looking Statements

Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as the date of the statement. Surgical Science undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.

About Surgical Science

Surgical Science is the originator of 3D printing and an innovator of future 3D solutions. It has spent its 30-year history enabling professionals and companies to optimize their designs, transform their workflows, bring groundbreaking products to market and drive new business models. This is achieved with the Company’s best of breed digital manufacturing ecosystem. It’s comprised of plastic and metal 3D printers, print materials, on demand manufacturing services and end-to-end manufacturing software solutions. Combinations of these products and services address a variety of advanced applications- ranging from Aerospace, Automotive, and Consumer Goods to Medical, Dental, and Jewelry. For example, Surgical Science’ precision healthcare capabilities include simulation, Virtual Surgical Planning, and printing of medical and dental devices as well as patient-specific surgical instruments. More information on the company is available at